OPDP Issues Untitled Letter About Sponsored Social Media Post

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

OPDP Issues Untitled Letter About Sponsored Social Media Post

J.W. Schomisch

September 1, 2023 at 04:36 PM EST

The FDA’s Office of Prescription Drug Promotion (OPDP) issued an Aug. 11 Untitled Letter to Exeltis USA Inc. alleging that a sponsored social media post for Slynd (drospirenone) tablets made false or misleading claims and representations about the drug’s risks and efficacy. “These violations are concerning from a public health perspective because the promotional communication... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

OPDP Issues Untitled Letter About Sponsored Social Media Post

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT